Experimental cancer drug AUR106 tested in humans for first time
NCT ID NCT05861947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug moves through the body. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AUR106 (an experimental drug taken by mouth)
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early, small Phase 1 trial (only 21 patients) focused on safety and dosing, not effectiveness. The trial was terminated, so results may be incomplete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
All India Institute of Medical Sciences
Bhubaneswar, Odisha, 751019, India
-
Kiran Multi Super Specialty Hospital
Surat, Gujarat, 395004, India
-
Moraya Multispeciality Hospital (Ashwin Medical Foundations)
Pune, Maharasthra, 411033, India
-
Omega Hospital
Visakhapatnam, Andhra Pradesh, 530040, India
-
Sankalp Speciality Hospital
Nashik, Maharashtra, 422009, India
-
Unique Hospital Multispeciality and Research Institute
Surat, Gujarat, 395002, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?